Zai Lab Ltd (9688)

Currency in HKD
16.47
-0.63(-3.68%)
Closed·
Earnings results expected in 5 days
9688 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16.2216.62
52 wk Range
12.3135.50
Key Statistics
Bid/Ask
16.47 / 16.48
Prev. Close
17.1
Open
16.36
Day's Range
16.22-16.62
52 wk Range
12.31-35.5
Volume
10.77M
Average Volume (3m)
11.04M
1-Year Change
-32.7755%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
9688 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
23.78
Upside
+44.35%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Zai Lab Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

8 Buy
2 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 23.78
(+44.35% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Goldman Sachs
Buy39.30+138.62%43.88Maintain08/09/2025

Earnings

Latest Release
26/02/2026
EPS / Forecast
-0.36 / -0.25
Revenue / Forecast
998.23M / 992.59M
EPS Revisions
Last 90 days

Compare 9688 to Peers and Sector

Metrics to compare
9688
Peers
Sector
Relationship
P/E Ratio
−13.8x−3.2x−0.5x
PEG Ratio
−0.36−0.190.00
Price/Book
3.4x6.6x2.6x
Price / LTM Sales
5.3x14.6x3.2x
Upside (Analyst Target)
27.8%236.0%47.8%
Fair Value Upside
Unlock2.6%6.7%Unlock

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Employees
1784
Market
Hong Kong

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
36.96M32.90%608.79M
Other Institutional Investors
54.42M48.44%896.29M
Public Companies & Retail Investors
20.97M18.66%345.39M
Total
112.35M100.00%1.85B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
RTW Investments, LP6.19%6,959,032114,615
FMR LLC5.13%5,765,60294,959

FAQ

What Is the Zai Lab (Hong Kong: 9688) Share Price Today?

The Zai Lab stock price today is 16.47 HKD.

What Stock Exchange Does Zai Lab (9688) Trade On?

Zai Lab is listed and trades on the Hong Kong Stock Exchange.

What Is the Ticker (Stock Symbol) for Zai Lab?

The stock symbol (also called a 'ticker') for Zai Lab is "9688."

What Is the Current Zai Lab Market Capitalisation?

As of today, Zai Lab (Hong Kong: 9688) market cap is 18.96B HKD.

What Is Zai Lab's (9688) Earnings Per Share (TTM)?

The Zai Lab EPS is currently -1.60 (Trailing Twelve Months).

When Is the Next Zai Lab Earnings Date?

Zai Lab's next earnings report will be released on 07/05/2026.

Is 9688 a Buy or Sell From a Technical Analyst Perspective?

Based on today's Zai Lab moving averages and other technical indicators, the daily buy/sell signal for 9688 stock is Strong Sell.

How Many Times Has Zai Lab Stock Split?

Zai Lab has split 1 times. (See the 9688 stock split history page for full effective split date and price information.)

How Many Employees Does Zai Lab Have?

Zai Lab has 1784 employees, based on their latest Companies House report.

What is the current trading status of Zai Lab (Hong Kong: 9688)?

As of 02/05/2026, Zai Lab (9688) is trading at a share price of 16.47 HKD, with a previous close of 17.10 HKD. The stock has fluctuated within a day range of 16.22 HKD to 16.62 HKD, while its 52-week range spans from 12.31 HKD to 35.50 HKD.

What Is Zai Lab (9688) Price Target According to Analysts?

The average 12-month price target for Zai Lab is 23.78 HKD, with a high estimate of 43.13479624 HKD and a low estimate of 15.03134796 HKD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +44.35% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.